Pharma solutions
Lipidor develops pharmaceuticals for skin with unique lipid based formulation opportunities for global pharma companies. Our proprietary delivery platform and expertise help pharma companies launch innovative, patient-friendly skin treatments, in record time.
Introduction
Our innovative and flexible delivery system AKVANO® brings a number of tangible benefits for pharmaceutical companies and patients alike.
Our focus is to reformulate existing generika to new, innovative candidates using our proprietary delivery platform AKVANO®. Reformulating existing substances enables a faster track through clinical trials to regulatory approval – and together with our clients – commercial launch.
The flexibility of the AKVANO® platform has enabled us to successfully incorporate more than 60 structurally very different active pharmaceutical ingredients, used in many different therapeutic applications. Applications such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anaesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema and anti-migraine.
Ease of use
AKVANO® formulations provide excellent cosmetic qualities, are quick and simple to use and dry quickly, leaving a pleasant feeling to the skin. Being inherently non-greasy and non-sticky means they can be worn comfortably under clothes without staining them.
Non-touch application
AKVANO® formulations allow non-touch application for sensitive skin. Non-touch application also minimises irritation for sensitive skin.
Reduced irritation
AKVANO® formulations do not require preservatives or additional components that may cause skin irritation. Furthermore, AKVANO® formulations reinforce the skin barrier function which render the skin less susceptible for irritation.
Increased patient compliance
The positive properties of AKVANO® mean it has the potential to increase compliance rates – leading to better efficacy outcomes, and increasing the willingness of physicians to prescribe the treatment to new patients.
Company
Lipidor is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in pre-clinical and clinical phases.
Lipidor update
Lipidor’s focus is on commercializing the drug candidate AKP02G2 and, with the implementation of a clinical Phase III study, the company is at a crucial stage of development. The main aim of the study is to compare the therapeutic effect of AKP02G2 against mild to moderate psoriasis with a market-leading product.
Business scope
The global demand for pharmaceuticals for skin is a large and growing market. With the revolutionary AKVANO® delivery platform, Lipidor is at the cutting-edge of innovation. Want to know more?